Jounce Therapeutics is an immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, a cell surface receptor expressed on macrophages; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells in solid tumors; JTX-4014, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and JTX-1811, a monoclonal antibody that deplete T regulatory cells in the tumor microenvironmen. The JNCE stock yearly return is shown above.
The yearly return on the JNCE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JNCE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|